tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Steven Lichtman, 118 are a BUY (88.72%), 15 are a HOLD (11.28%).
Analyst Steven Lichtman, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 65.24% that have a potential upside of 28.63% achieved within 173 days.
Steven Lichtman’s has documented 288 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on DXCM, DexCom at 25-Oct-2024.
Analyst best performing recommendations are on CFMS (CONFORMIS).
The best stock recommendation documented was for TNDM (TANDEM DIABETES CARE) at 2/27/2019. The price target of $68 was fulfilled within 2 days with a profit of $6.14 (9.93%) receiving and performance score of 49.63.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$110
$21.05 (23.66%)
$100
3 days ago
(18-Dec-2024)
9/11 (81.82%)
$20.04 (22.28%)
169
Buy
$110
$21.05 (23.66%)
$85
5 days ago
(16-Dec-2024)
5/6 (83.33%)
$18.69 (20.47%)
378
Buy
$110
$21.05 (23.66%)
$100
9 days ago
(12-Dec-2024)
17/19 (89.47%)
$19.08 (20.99%)
437
Buy
$107
$18.05 (20.29%)
$98
10 days ago
(11-Dec-2024)
14/17 (82.35%)
$16.51 (18.25%)
296
Buy
$100
$11.05 (12.42%)
$98
10 days ago
(11-Dec-2024)
8/10 (80%)
$9.51 (10.51%)
159
Which stock is Steven Lichtman is most bullish on?
Which stock is Steven Lichtman is most reserved on?
What Year was the first public recommendation made by Steven Lichtman?
